Key Points from "Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR":

The study compares two strategies for managing LDL cholesterol in coronary artery disease (CAD):

Treat-to-target: aiming for LDL levels between 50-70 mg/dL.

High-intensity statin: prescribing the highest tolerated statin dose regardless of LDL level.

Both strategies are equally effective in preventing major adverse cardiovascular events (MACE) over 3 years:

MACE rate: 8.1% in treat-to-target vs. 8.7% in high-intensity statin (non-inferior).

No significant differences in individual components of MACE (death, MI, stroke, revascularization).

Treat-to-target achieved lower LDL levels initially but the gap closed by year 3.

Safety was similar between groups, but new-onset diabetes trended lower in treat-to-target.

Study limitations:

Open-label design (not blinded).

Limited use of combination therapy (e.g., ezetimibe) with statins.

Implications:

Treat-to-target offers an alternative to the "fire and forget" approach.

May be more patient-centered, allowing dose adjustment based on individual response.

Further research is needed on longer-term outcomes and lower LDL targets.

Additional points:

European guidelines recommend even lower LDL targets (<55 mg/dL) for high-risk patients.

Concerns remain about the potential side effects of high-intensity statin therapy.

Treat-to-target may offer a more cautious and personalized approach.

Link to article: doi:10.1001/jama.2023.2487